Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

87.11
-0.3600-0.41%
Post-market: 87.02-0.0900-0.10%19:30 EDT
Volume:1.09M
Turnover:94.72M
Market Cap:12.27B
PE:-38.14
High:88.46
Open:87.90
Low:85.94
Close:87.47
52wk High:95.49
52wk Low:20.45
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.09
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:26.36
PE(LYR):-7,144.26

Loading ...

BRIEF-Arrowhead Pharmaceuticals Q2 EPS USD -0.93

Reuters
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Income USD -141.26 Million

THOMSON REUTERS
·
May 08

Corrected-Arrowhead Pharmaceuticals Q2 Net Income USD -132.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 08

Arrowhead Pharmaceuticals Q2 Operating Expenses USD 214.997 Million

THOMSON REUTERS
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Arrowhead Pharmaceuticals - Madrigal to Pay $25 Mln Upfront and up to $975 Mln in Milestones to Arrowhead

THOMSON REUTERS
·
May 05

Arrowhead Pharmaceuticals - Eligible for Tiered Royalties on Commercial Sales

THOMSON REUTERS
·
May 05

Arrowhead licenses ARO-PNPLA3 MASH drug to Madrigal for USD 25 million upfront

Reuters
·
May 05

Arrowhead Pharmaceuticals to present at BofA Securities 2026 Healthcare Conference

Reuters
·
May 04

Arrowhead Pharmaceuticals Initiated at Overweight by JP Morgan

Dow Jones
·
May 01

Arrowhead says Australia TGA approves REDEMPLO for familial chylomicronemia syndrome

Reuters
·
May 01

Arrowhead Pharmaceuticals Receives Tga Approval of Redemplo® (Plozasiran) in Australia, Expanding Global Access for Patients With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
May 01

Arrowhead Pharmaceuticals - Phase 3 Study Shows Redemplo Reduces Triglycerides by Median 80% From Baseline

THOMSON REUTERS
·
May 01

JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target

MT Newswires Live
·
May 01

Arrowhead Pharmaceuticals : JP Morgan Initiates Coverage With Overweight Rating; Target Price $88

THOMSON REUTERS
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153%, and institutional views are bullish

Earnings Agent
·
May 01

Earning Preview: Arrowhead Pharmaceuticals this quarter’s revenue is expected to increase by 153.09%, and institutional views are bullish

Earnings Agent
·
May 01

A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After EMA CHMP Backs REDEMPLO For FCS

Simply Wall St.
·
Apr 28

Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts

TIPRANKS
·
Apr 25

Arrowhead CFO Daniel Joseph Apel disposes of common shares worth $921,276

Reuters
·
Apr 25